Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2015 Dec;2(4):205-209.
doi: 10.1093/nop/npv037. Epub 2015 Sep 29.

Response Assessment in Neuro-Oncology (RANO): more than imaging criteria for malignant glioma

Susan M Chang  1 , Patrick Y Wen  1 , Michael A Vogelbaum  1 , David R Macdonald  1 , Martin J van den Bent  1
Affiliations
Review

Response Assessment in Neuro-Oncology (RANO): more than imaging criteria for malignant glioma

Susan M Chang et al. Neurooncol Pract. 2015 Dec.

Abstract

The introduction of antiangiogenic therapies for the treatment of malignant glioma and the effect of these agents on standard imaging studies were the stimuli for forming a small group of investigators to critically evaluate the limitations of the Macdonald criteria in assessing response to treatment. The initial goal of this group was to highlight the challenges in accurately determining the efficacy of therapeutic interventions for malignant glioma and to develop new criteria that could be implemented in clinical care as well as in the design and conduct of clinical trials. This initial Response Assessment in Neuro-Oncology (RANO) effort started in 2008 and over the last 7 years, it has expanded to include a critical review of response assessment across several tumor types as well as endpoint selection and trial design to improve outcome criteria for neuro-oncological trials. In this paper, we review the overarching principles of the RANO initiative and the efforts to date. We also highlight the diverse and expanding efforts of the multidisciplinary groups of investigators who have volunteered their time as part of this endeavor.

Keywords: Response Assessment in Neuro-Oncology (RANO) criteria; malignant glioma.

PubMed Disclaimer

References

    1. van den Bent MJ, Vogelbaum MA, Wen PY et al. End point assessment in gliomas: novel treatments limit usefulness of classical Macdonald's Criteria. J Clin Oncol. 2009;27(18):2905–2908. - PMC - PubMed
    1. Wen PY, Macdonald DR, Reardon DA et al. Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol. 2010;28(11):1963–1972. - PubMed
    1. van den Bent MJ, Wefel JS, Schiff D et al. Response assessment in neuro-oncology (a report of the RANO group): assessment of outcome in trials of diffuse low-grade gliomas. Lancet Oncol. 2011;12(6):583–593. - PubMed
    1. Vogelbaum MA, Jost S, Aghi MK et al. Application of novel response/progression measures for surgically delivered therapies for gliomas: Response Assessment in Neuro-Oncology (RANO) Working Group. Neurosurgery. 2012;70(1):234–243, discussion 243-4. - PubMed
    1. Reardon DA, Galanis E, DeGroot JF et al. Clinical trial end points for high-grade glioma: the evolving landscape. Neuro Oncol. 2011;13(3):353–361. - PMC - PubMed